254 related articles for article (PubMed ID: 29773427)
1. Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall.
Mohanty SK; Sharma S; Pradhan D; Kandukuri SR; Farahani N; Barry C; Wu JM; Frishberg D; Balzer B
Pathol Res Pract; 2018 Jun; 214(6):821-825. PubMed ID: 29773427
[TBL] [Abstract][Full Text] [Related]
2. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics.
Koch MB; Shih IM; Weiss SW; Folpe AL
Am J Surg Pathol; 2001 Jan; 25(1):58-64. PubMed ID: 11145252
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
[TBL] [Abstract][Full Text] [Related]
4. MITF positivity in atypical fibroxanthoma: a diagnostic pitfall.
Tallon B; Beer TW
Am J Dermatopathol; 2014 Nov; 36(11):888-91. PubMed ID: 25238448
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of p16 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions.
Smith EH; Lowe L; Harms PW; Fullen DR; Chan MP
J Cutan Pathol; 2016 Aug; 43(8):671-8. PubMed ID: 27152444
[TBL] [Abstract][Full Text] [Related]
7. Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
Ricci C; De Leo A; Dika E; Lambertini M; Veronesi G; Corti B
Acta Histochem; 2020 Feb; 122(2):151498. PubMed ID: 31889532
[TBL] [Abstract][Full Text] [Related]
8. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of ERG immunostaining in dermatofibroma.
Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y
J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257
[TBL] [Abstract][Full Text] [Related]
10. [Fibrohistiocytic skin tumors].
Hügel H
J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
[TBL] [Abstract][Full Text] [Related]
11. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ.
Hillesheim PB; Slone S; Kelley D; Malone J; Bahrami S
J Cutan Pathol; 2011 Jul; 38(7):565-9. PubMed ID: 21362015
[TBL] [Abstract][Full Text] [Related]
14. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
15. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
16. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
17. Mast cells in cutaneous tumors: innocent bystander or maestro conductor?
Biswas A; Richards JE; Massaro J; Mahalingam M
Int J Dermatol; 2014 Jul; 53(7):806-11. PubMed ID: 23621615
[TBL] [Abstract][Full Text] [Related]
18. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
Kanner WA; Brill LB; Patterson JW; Wick MR
J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases.
Buonaccorsi JN; Prieto VG; Torres-Cabala C; Suster S; Plaza JA
Am J Dermatopathol; 2014 Feb; 36(2):124-30. PubMed ID: 23782678
[TBL] [Abstract][Full Text] [Related]
20. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
